NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/17/2026 11:21
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,214.57 mln
Float12.74 mln
Earnings Date11/17/2026
1-Year Forecast
231
Exceptional upside
Relative Strength
81
/ 100
Strongly outperforming
Debt / Equity
0.10
Very low leverage
ROE
-54.73
Deeply negative
ROA
-42.99
Deeply negative
Business Description
Palvella Therapeutics is a Wayne, Pennsylvania-based medical company working to bring new treatments to people living with rare and serious inherited skin conditions. Its primary focus is a topical gel called QTORIN rapamycin, which is currently being tested in late-stage clinical trials for patients with certain vascular skin disorders. The company is also exploring additional uses of this gel, along with a separate treatment called QTORIN pitavastatin, targeting other hard-to-treat skin diseases.